Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Omeros Corporation

Market Cap 70Cr 60Cr 55Cr 52Cr 98Cr 6.58TCr 99Cr 655.79Cr 255.32Cr 3.23TCr 261.86Cr 256.26Cr 11TCr P/E 2026 *
29.2x
P/E 2027 * -49x
Enterprise Value 70Cr 60Cr 55Cr 52Cr 98Cr 6.58TCr 99Cr 655.79Cr 255.32Cr 3.23TCr 261.86Cr 256.26Cr 11TCr EV / Sales 2026 *
10.3x
EV / Sales 2027 * 4.87x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day+1.69%
1 week-5.49%
Current month-12.68%
1 month-21.31%
3 months-14.46%
6 months+9.17%
Current year-43.87%
1 week 6.7
Extreme 6.7023
10.11
1 month 6.7
Extreme 6.7023
12.55
Current year 6.7
Extreme 6.7023
17.63
1 year 2.95
Extreme 2.95
17.65
3 years 0.92
Extreme 0.92
17.65
5 years 0.92
Extreme 0.92
17.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap.
22/05Fiscal year

Director

22,500 0.0313%
18/02Fiscal year

Chief Executive Officer

11,57,678 1.6328%
12/01Sell

Chief Financial Officer

1,20,000 0.1693%
Change 5-day change 1-year change 3-year change Capi.($)
+1.69%-5.49%+200.31%+61.47% 69Cr
+3.23%+2.25%+65.02%+113.87% 5.45TCr
+0.04%+5.05%+43.44%+36.75% 4.39TCr
+3.04%+7.05%-12.15%-18.06% 2.26TCr
+3.07%+7.15%-1.82%+392.25% 2.07TCr
-0.53%+0.54%+16.19%-37.07% 1.58TCr
+5.27%+1.87%+13.67%-38.81% 1.48TCr
+0.65%-0.27%+26.80%+174.70% 1.31TCr
-5.17%+0.50%+21.80% - 1.27TCr
-0.27%+6.06%+78.78%+104.79% 1.16TCr
Average +1.10%+1.08%+45.20%+87.76% 2.1TCr
Weighted average by Cap. +1.53%+1.96%+34.56%+90.59%

Financials

2026 *2027 *
Net sales 6.78Cr 5.85Cr 5.38Cr 5.06Cr 9.52Cr 640.17Cr 9.6Cr 64Cr 25Cr 314.18Cr 25Cr 25Cr 1.09TCr 14Cr 12Cr 11Cr 11Cr 20Cr 1.35TCr 20Cr 134.66Cr 52Cr 663.57Cr 54Cr 53Cr 2.3TCr
Net income 2.12Cr 1.83Cr 1.68Cr 1.59Cr 2.98Cr 200.39Cr 3Cr 20Cr 7.77Cr 98Cr 7.97Cr 7.8Cr 340.22Cr -2.19Cr -1.89Cr -1.74Cr -1.63Cr -3.07Cr -206.68Cr -3.1Cr -21Cr -8.01Cr -101.43Cr -8.22Cr -8.04Cr -350.91Cr
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
17/26/17 9.640 $ +1.69% 14,16,883
16/26/16 9.480 $ +1.61% 26,08,247
15/26/15 9.330 $ +6.81% 19,60,054
12/26/12 8.735 $ -14.19% 77,84,719
11/26/11 10.18 $ -0.20% 10,97,428
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
9.640USD
Average target price
40.00USD
Spread / Average Target
+314.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!